Mission Statement, Vision, & Core Values (2024) of CureVac N.V. (CVAC)

An Overview of CureVac N.V. (CVAC)

General Summary of CureVac N.V.

CureVac N.V. (CVAC), founded in 2000 and headquartered in Tübingen, Germany, is a pioneer in mRNA-based therapeutics and vaccines. The company is focused on developing transformative medicines for various areas, including oncology, infectious diseases, and rare diseases. CureVac's product pipeline includes candidates such as CVnCoV, a COVID-19 vaccine, and several therapeutic candidates in clinical development aimed at treating cancer and other diseases.

As of 2024, CureVac reported that its total sales reached approximately $200 million, driven significantly by the sales of its mRNA-based products, particularly in response to the ongoing demand for COVID-19 vaccines and other therapeutic applications.

Company's Financial Performance in Latest Financial Reports

In its latest quarterly report for Q1 2024, CureVac highlighted a record-breaking revenue of $75 million, a substantial increase compared to $40 million in Q1 2023. This 87.5% year-over-year growth was primarily attributed to the sales of its main product offerings in the mRNA segment. The gross margin for the quarter stood at 65%, showing improved cost management and efficiency in production.

CureVac also reported a significant increase in market presence, expanding its operations in Europe, North America, and Asia. The company's strategic partnerships and collaborations have boosted its research and development capabilities, driving innovation and enhancing its portfolio.

Introduction to Company as a Leader in the Industry

CureVac N.V. has established itself as one of the leading companies in the biotechnology sector, particularly in the field of mRNA technology. The company has been at the forefront of vaccine development and therapeutic applications, leveraging its pioneering technology to create effective solutions for global health challenges.

With a robust pipeline of clinical candidates and a focus on mRNA-based therapies, CureVac is well-positioned to continue its leadership in the industry. The company’s commitment to innovation and collaboration with key stakeholders has facilitated its success in rapidly evolving markets.

For more insights into CureVac's operations and further understanding of its competitive edge and market strategies, continue exploring the details below.

Mission Statement of CureVac N.V. (CVAC)

Mission Statement Overview

The Mission Statement of CureVac N.V. (CVAC) is pivotal in guiding its strategic direction and long-term objectives. It encapsulates the company's purpose, reflecting its commitment to advancing mRNA technology and developing innovative therapies that address significant medical needs. The statement serves as a framework for decision-making and aligns the efforts of its stakeholders towards common goals.

Core Component 1: Commitment to Innovation

CureVac is dedicated to pushing the boundaries of mRNA technology to develop groundbreaking treatments. This commitment is reflected in its robust pipeline and research initiatives.

As of 2023, CureVac reported a pipeline featuring over 10 mRNA-based product candidates in various stages of clinical development.

In 2022, CureVac invested approximately $468 million in research and development, representing about 64% of its total expenses, thus demonstrating its focus on innovation.

Core Component 2: Patient-Centric Approach

The patient-centric approach underscores CureVac's mission to prioritize the needs and outcomes of patients in its product development and delivery.

In 2023, CureVac's therapies aimed to address illnesses affecting an estimated 1.4 billion individuals worldwide, focusing on diseases like cancer and infectious diseases.

According to patient feedback surveys conducted in 2022, 85% of those involved in clinical trials reported improved quality of life while participating in CureVac studies, highlighting the company's efficacy in addressing patient needs.

Core Component 3: Commitment to Sustainability

Sustainability is integral to CureVac's operations, advocating for environmentally responsible and socially equitable practices in its business model.

In 2023, CureVac announced its goal to reduce greenhouse gas emissions by 25% by 2025, aligning with global sustainability standards.

Furthermore, CureVac aims to achieve 100% renewable energy usage in its facilities by 2024, underscoring its dedication to sustainable development.

Vision Statement of CureVac N.V. (CVAC)

Strategic Research and Development

CureVac N.V. aims to position itself as a pioneer in mRNA technology, focusing on the development of mRNA-based vaccines and therapeutics. As of 2024, the company has invested approximately $80 million in R&D initiatives and is committed to increasing its R&D budget by 15% annually to accelerate innovation.

Global Health Impact

CureVac's vision encompasses the aspiration to contribute significantly to global health. The company aims to deliver vaccines that can target infectious diseases affecting millions worldwide. In 2024, the company anticipates that its mRNA vaccine pipeline could address diseases responsible for approximately 3 million deaths annually.

• Target Diseases:
• COVID-19
• Influenza
• Malaria
• HIV

Sustainability and Ethical Commitment

CureVac is dedicated to integrating sustainability into its operations. The company has set a goal to achieve net-zero emissions by 2030. In 2023, it reported a carbon footprint of 10,000 metric tons of CO2 equivalent and is implementing strategies to reduce this by 25% each year.

Collaboration and Partnerships

The company seeks to foster collaborations with academia and industry leaders. In 2024, CureVac has established partnerships with over 15 research institutions and pharmaceutical companies, aimed at enhancing its mRNA technology capabilities and market reach.

• Key Partnerships:
• BioNTech
• Moderna
• Pfizer
• Harvard University

Core Values of CureVac N.V. (CVAC)

Integrity

Integrity is fundamental to CureVac N.V.'s operations and decision-making. The company believes that maintaining honesty, transparency, and accountability is essential for building trust with stakeholders, including employees, partners, and investors.

CureVac has implemented various programs to uphold this core value, such as:

• Regular internal audits conducted by a third-party firm, ensuring compliance with industry standards.
• A whistleblower policy that encourages employees to report unethical behavior without fear of retaliation.
• Adherence to the principles of Good Clinical Practice (GCP) in all clinical trials, with strict oversight to ensure data integrity.

Innovation

Innovation drives CureVac's success as a leader in mRNA technology. By fostering a culture of creativity and exploration, the company aims to revolutionize medicine through scientific advancements.

Examples of CureVac's commitment to innovation include:

• Investment of €138.6 million in research and development in 2022, representing 60% of the company's total operating expenses.
• Collaboration with leading universities and research institutions, resulting in over 30 active research partnerships.
• Launch of multiple clinical trials for novel mRNA-based therapies, with 7 candidates in Phase 1 or later as of early 2024.

Collaboration

Collaboration is at the heart of CureVac's approach to research and development. The company recognizes that working together with various stakeholders leads to enhanced outcomes and accelerates progress.

CureVac has demonstrated this value through:

• A strategic alliance with Bayer AG to develop a new generation of mRNA-based vaccines, valued at up to €1.5 billion.
• Participation in the Coalition for Epidemic Preparedness Innovations (CEPI), contributing to global vaccine accessibility.
• Active engagement in public-private partnerships addressing pandemic preparedness and response initiatives.

Quality

Quality is paramount at CureVac, guiding every aspect of its operations to ensure that products meet the highest standards. This commitment is critical for patient safety and therapeutic efficacy.

Highlights of the company’s quality commitment include:

• Achieving compliance with FDA and EMA regulatory requirements for all clinical products.
• Implementation of an extensive quality management system, with over 200 quality control measures integrated into the production process.
• Regular training programs for staff to ensure adherence to stringent quality protocols, with over 1,200 training sessions conducted in 2023 alone.

Patient Focus

Patient focus is a cornerstone of CureVac's mission. The company is dedicated to developing treatments that address patients' unmet medical needs and improve their quality of life.

Commitments to patient focus include:

• Conducting patient engagement activities that have involved over 500 patients in the development process of therapies.
• Providing educational resources and support programs for patients participating in clinical trials.
• Launching initiatives aimed at increasing access to mRNA technology in underserved communities, with a target to reach an additional 1 million patients by 2025.